NICE Final guidance: Myelofibrosis - ruxolitinib (review of TA289) [831]

We are happy to share with everyone a very positive outcome from the NICE review of ruxolitinib. 

Particular thanks to everyone who responded to information requests, our patient attendees, patient advocacy teams and clinical experts.

What has NICE said?

Ruxolitinib (Jakavi) is recommended as a possible treatment for treating disease-related splenomegaly or symptoms in adults with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis only if they have intermediate-2 high risk disease.

What does this mean for patients?

If you have an enlarged spleen or symptoms caused by one of these types of myelofibrosis, and your doctor thinks that Ruxolitinib is the right treatment, you should be able to have the treatment on the NHS.

Ruxolitinib should be available on the NHS within 3 months of the guidance being issued.

If you are not eligible for treatment you should be able to continue taking Ruxolitinib until you and your doctor decide it is the right time to stop.

Please continue reading the NICE notification to the public here... you can also read the full guidance notes published by NICE.